Regeneron Bounces Higher Off Support

The S&P 500 may have pulled back yesterday, but the Nasdaq Composite didn’t. The tech heavy index actually closed within just a few points of a new bull market high.

Being the case, its not too surprising that most biotech stocks also rallied yesterday. Some biotechs, such as Bluebird Bio (NASDAQ: BLUE), actually hit new highs.

Other biotech stocks simply got a nice bounce, and one of those would be Regeneron Pharmaceuticals, which is highlighted below.

Regeneron discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide.

The company has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies, and a license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA.

Review the 1-year chart of Regeneron with the added notations:

Regeneron has been on a nice, slow, steady rise for most of the past year.

Over the last 3 months, the stock has been bouncing along a common chart formation known as a trendline support. On Friday Regeneron tested that trendline for the 4th time.

Now that the stock has bounced, higher prices should follow, thus investors and traders could look to enter a long position.

However, if Regeneron were to roll over and break below the trendline, lower prices should follow.

The stock closed yesterday at $463.22/share.

No matter what your strategy, or when you decide to enter, always remember to use protective stops and you’ll be around for the next trade. Capital preservation is always key.

Posted to The Biotech Trader on Apr 21, 2015 — 9:04 PM
Comments ({[comments.length]})
Sort By:
Loading Comments
No comments. Break the ice and be the first!
Error loading comments Click here to retry
No comments found matching this filter
Want to add a comment? Take me to the new comment box!